Assessing India’s Innovation Climate
In 2005 India mostly strengthened their patent laws to meet international norms, with the distinct requirement that new drug products […]
In 2005 India mostly strengthened their patent laws to meet international norms, with the distinct requirement that new drug products […]
In 2005 India mostly strengthened their patent laws to meet international norms, with the distinct requirement that new drug products
The Scientific American WorldView project, where I’ve been serving as lead editorial consultant, is ramping up for its May 20th
I’ll be giving a talk at the Kogod School of Business on Tuesday February 24th on “Drug Development – Balancing
Drug Development – Balancing National and Commercial Needs Read Post »
Emergent biotechnology companies are very reliant on capital, often having less than two years capital on hand. Like other businesses
I’m working on an International Biotechnology ranking and comparison for a well-known publication, and am looking for data sets comparing
A lot of people have been asking my opinion on when a concise generic biologic regulatory pathway will emerge in
When will the U.S. develop concise generic biologic rules? Read Post »
I recently had the opportunity to conduct a brief interview with Mireille Gingras, Ph.D. President and CEO of HUYA Bioscience
My recent presentation at the “Biotechnology for Turkey” conference has been posted online. My central thesis was that the challenges
I’ll be speaking at the Biotech for Turkey conference in Istanbul on November 7th. This conference, convened by Bosfor Biotech